A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Number of Participants with Ocular and Systemic Treatment-emergent Adverse Events (TEAEs)

Number of participants with ocular and systemic TEAEs will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as any adverse event occurring at or after the administration of study intervention.

Time frame: Upto 5 Years

Number of Participants with Abnormal Findings in Clinical Laboratory Assessments

Number of participants with abnormal findings in clinical laboratory Assessments (including hematology and clinical chemistry) will be reported.

Time frame: Upto 5 Years

Number of Participants with Abnormal Findings in Retinal imaging and Eye Examinations

Number of participants with abnormal findings in retinal imaging (Fundus Autofluorescence, Spectral Domain Optical Coherence Tomography, Color Fundus Photography) and eye examinations will be reported.

Time frame: Upto 5 Years